Mechanisms regulating stem cell phenotype in infantile hemangioma by Richmond, Niamh
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
7-15-2016 12:00 AM 
Mechanisms regulating stem cell phenotype in infantile 
hemangioma 
Niamh Richmond 
The University of Western Ontario 
Supervisor 
Dr. Zia A. Khan 
The University of Western Ontario 
Graduate Program in Pathology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Niamh Richmond 2016 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Medical Cell Biology Commons, Medical Molecular Biology Commons, and the Medical 
Pathology Commons 
Recommended Citation 
Richmond, Niamh, "Mechanisms regulating stem cell phenotype in infantile hemangioma" (2016). 
Electronic Thesis and Dissertation Repository. 3835. 
https://ir.lib.uwo.ca/etd/3835 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
ABSTRACT 
Infantile hemangiomas (IHs) are benign vascular neoplasms characterized by the differentiation 
of multipotential stem cells (hemSCs) into endothelial cells during the early proliferative phase, 
and later into adipocytes during spontaneous involution. Transforming growth factor-β (TGFβ) 
has been shown to be significantly elevated upon IH involution and this coincides with 
repression of a developmentally-regulated transcription factor T-box 2 (TBX2). These findings 
implicate both TGFβ and TBX2 in mediating hemSC differentiation during IH evolution. The 
aim of my study is to understand the role of TGFβ and TBX2 in hemSC differentiation. 
I performed immunofluorescence staining to localize TBX2 protein in sectioned IH tissues. I 
then characterized hemSCs isolated from IH patient specimens for TBX2 expression through 
mRNA analysis and cell staining. To determine the role of TBX2 in hemSC differentiation, I 
cultured the cells in mesenchymal, endothelial, neuroglial, and hematopoietic induction media 
following TBX2 knockdown. Next, I studied the potential downstream targets by conducting 
expression analysis for cell cycle regulators, pluripotency factors, and T-box family members. 
To investigate potential upstream regulators of TBX2, I cultured hemSCs with the addition of 
exogenous TGFβ, and an inhibitor of TGFβ signaling pathway. To confirm functional response 
of hemSCs to the treatments, expression of TGFβ-responsive genes collagen I and IV was 
assessed. 
My results show that TBX2 is expressed and primarily localized to the nuclei of hemSCs; the 
level of expression varied between cultures of different patient-derived hemangiomas. HemSCs 
showed morphological changes upon differentiation towards mesenchymal, endothelial, and 
neuroglial lineages. TBX2 knockdown caused upregulation of hematopoietic lineage markers 
CD34, CD45, and ckit. Pluripotency factor and cell cycle regulator p16 expression was also 
upregulated upon TBX2 knockdown. Lastly, my studies show that TGFβ represses TBX2 
expression, which correlates with upregulated pluripotency factor expression. 
My studies suggest that TBX2 modulates the differentiation-competence of hemSCs. TBX2 may 
in turn be regulated by TGFβ during IH involution. Understanding the signaling mechanisms 
regulated by TBX2 may provide a novel target pathway to promote premature involution of IH 
as a therapeutic option for patients. 
Keywords: Infantile hemangioma, T-box 2, TGFβ, stem cells, differentiation, pluripotency 
 
ii 
 
ACKNOWLEDGEMENTS 
I express my deepest gratitude to my supervisor, Dr. Zia A. Khan:   
Your unwavering guidance and support has enabled me to successfully progress in my studies.  I 
thank you for your continuing encouragement, and support in all of my endeavours.  You have 
provided me with a tremendously enriching environment through which I have acquired both 
scientific knowledge and personal development.  It has been a privilege to be a part of the Khan 
lab, and to learn from an admirable scientific role model.   
I would like to extend my thanks to my Advisory Committee members Dr. Christopher Howlett, 
Dr. Thomas Drysdale, and Dr. Cheryle Seguin, for their guidance throughout my studies, and 
genuine support of my scientific success. 
I would also like to express my appreciation to my examination committee Dr. Lisa Cameron, 
Dr. Mark Darling, and Dr. Silvia Penuela.  Thank you for volunteering your time to take part in 
my thesis defense.     
 
 
 
 
 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
Abstract ................................................................................................................................ i 
Acknowledgments.............................................................................................................. iii 
Table of Contents ............................................................................................................... iv 
List of Figures . .................................................................................................................. vi 
List of Tables . .................................................................................................................. .ix 
List of Appendices ............................................................................................................ ..x 
List of Abbreviations . ....................................................................................................... xi 
1 INTRODUCTION ........................................................................................................ 1 
1.1     Infantile Hemangioma ........................................................................................ 1 
1.1.1  Clinical features of hemangioma ........................................................................ 1 
1.1.2  Current therapies for hemangioma...................................................................... 2 
1.1.3  Etiology of hemangioma .................................................................................... .3 
       1.1.4  Aberrant signalling pathways in hemangioma .................................................... 5 
1.1.5  Stem cells in hemangioma .................................................................................. 6 
 
1.2     Transcription factor T-box 2  .............................................................................. 9 
1.2.1  Known functional roles of T-box 2 in development ......................................... 10 
1.2.2  Known regulators of T-box 2 ............................................................................ 12 
1.2.3  Known functional roles of T-box 2 in tumourigenesis ..................................... 13 
2 PURPOSE AND OBJECTIVES OF THESIS ......................................................... 15 
2.1    Purpose of thesis ................................................................................................. 15 
2.2    Hypothesis and objectives of thesis .................................................................... 16 
3 MATERIALS AND METHODS .............................................................................. 17 
3.1     Hemangioma specimens and immunostaining .................................................. 17 
3.2    Cell culture ......................................................................................................... 17 
iv 
 
3.3    Differentiation assays .......................................................................................... 18 
3.4   Cellular transfection with siRNA ......................................................................... 19 
3.5   Cell viability assay ............................................................................................... 19 
3.6   RNA isolation and qRT-PCR ............................................................................... 20 
3.7   Signalling network assays .................................................................................... 22 
3.8   Statistical analysis………………………………..……………...……......……..23 
4 RESULTS ................................................................................................................... 24 
4.1  TBX2 localization in hemangioma ...................................................................... 24 
4.2  HemSCs express T-box transcription factors ....................................................... 26 
4.3  TBX2 modulation of hemSC cell cycle regulation .............................................. 29 
4.4  TBX2 modulation of hemSC pluripotency .......................................................... 32 
4.5  HemSCs exhibit multi-lineage differentiation potential ...................................... 35 
4.6  TBX2 modulation of hemSC differentiation-competence ................................... 39 
4.7  TBX2 potentially labels hemangioma cell of origin ............................................ 43 
4.8  TGF-β modulates TBX2 expression .................................................................... 45 
4.9  TGF-β modulates hemSC differentiation ............................................................. 48  
5 DISCUSSION ............................................................................................................. 50 
 5.1   Discussion of experimental findings……………………………………….……50 
 5.2   Clinical implications of study…………………………………………………. . 55 
 5.3   Future directions………………………………………………………………... 56 
6 REFERENCES ........................................................................................................... 58 
APPENDIX: SUPPLEMENTARY DATA ..................................................................... .66 
CURRICULUM VITAE .................................................................................................. .69 
 
  
v 
 
 
LIST OF FIGURES 
FIGURE DESCRIPTION              PAGE 
1.1  Current theories of hemangioma etiology..…………………………………..4 
2.1  Stem cell-derived cellular constituents of infantile hemangioma…. ………15 
2.2  Mechanisms regulating differentiation-competence of hemSCs...………… 16 
4.1  Nuclear localization of TBX2 in infantile hemangioma…………………… 25 
4.2.1 Nuclear and cytoplasmic localization of TBX2 in primary hemSC 
cultures…...………………………………………………………………… 27 
4.2.2 Expression of TBX2 in hemSCs preparations……….………………....…..27 
4.2.3  TBX2 expression in normal bm-MPCs…...………………………………...28 
4.2.4  T-box family expression profile in hemSCs and bm-MPCs….…………….28 
4.3.1  Cell cycle regulator expression in different primary hemSC cultures…...… 30 
4.3.2 Cell cycle regulator p16 expression is upregulated upon TBX2               
knockdown in hemSCs..…………………………………………………….30 
4.3.3 HemSC cultures with TBX2 knockdown demonstrate significant                
decrease in total live cell numbers.……………………………………...….31 
4.4.1  Pluripotency factor expression in different primary hemSC cultures……… 33 
4.4.2  TBX2 co-localizes with pluripotency factor OCT4 in IH specimens……… 33 
4.4.3  Pluripotency factors are upregulated upon TBX2 knockdown 
in hemSCs…………………………………………………………………...34 
vi 
 
4.5.1  HemSCs demonstrate differentiation-competence towards endothelial, 
neuroglial, and mesenchymal lineages ……………………………………..36 
4.5.2  Morphological differences observed in hemSC cultures with control,  
neuroglial, and adipogenic induction media………………………………..36 
4.5.3  Plating density for optimal hematopoietic activity…..…………………….. 37 
4.5.4  HemSCs do not exhibit intrinsic hematopoietic activity..…...…..…………38 
4.6.1  TBX2 knockdown delays CD31 expression upon culture of hemSCs in 
endothelial induction media….…………………………………………….. 40 
4.6.2  Morphological observations of hemSC cultures after transfection with 
TBX2 siRNA in control and endothelial induction media….……………… 40 
4.6.3 TBX2 knockdown does not alter TUBB3 or GFAP expression upon             
culture of hemSCs in neuroglial induction media…………………………..40 
4.6.4  Morphological observations of hemSC cultures after transfection  
with TBX2 siRNA in control and neuroglial induction media……………..41 
4.6.5  HemSCs exhibit upregulated hematopoietic lineage marker expression  
upon TBX2 knockdown…………………………………………………….42 
4.7.1   GLUT1 mRNA is upregulated in hemSCs upon TBX2 knockdown………44 
4.7.2  Fetal liver cells express TBX2 and GLUT1 in culture.…………………….44 
4.8.1  Screening for upstream modulators of TBX2 reveals TGFβ to significantly 
repress TBX2 mRNA levels…...…………………………………………....47 
4.8.2  TGFβ repression of TBX2 mRNA is rescued by the addition of 
TGFβ receptor inhibitor…………………………………………………….47 
4.8.3  TGFβ repression of TBX2 mRNA is ensued by upregulation  
of pluripotency factor expression…...……………………………………...47 
vii 
 
4.9.1  Addition of TGFβ to endothelial induction media significantly represses        
TBX2 mRNA…...………………………………………………………….. 49 
4.9.2  Addition of TGFβ to endothelial induction media significantly represses  
CD31 expression of hemSCs…..................................................................... 49 
5.1  Schematic diagram illustrating the hypothesis and acquired findings…......54 
Figure 1-App Confirmation of GLUT1-positive hemangioma specimens…………………66 
Figure 2-App Pluripotency factor and CD45 expression is dependent on the degree  
of TBX2 knockdown...……………………………………………………...67 
Figure 3-App Pluripotency factor upregulation by TGFβ is time-dependent......................67 
Figure 4-App Hematopoietic lineage induction of hemSCs upon TGFβ treatment……….68 
Figure 5-App Clinical perspectives: Effect of propranolol on TBX2 expression…………68 
 
 
 
 
 
 
 
 
  
viii 
 
LIST OF TABLES  
 
Table 1: List of primers used in this study............................................................................ 20 
Table 2: List of treatments used in this study........................................................................ 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF APPENDICES 
 
Appendix 1: Supplementary data………............................................................................... 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF ABBREVIATIONS 
 
bm-MNCs  Bone marrow mononuclear cells 
bm-MPCs   Bone marrow mesenchymal progenitor cells 
C/EBP   CCAAT/enhancer binding protein  
CD133   Cluster of differentiation-133; human stem cell antigen 
CD31   Cluster of differentiation-31; human endothelial cell antigen (PECAM-1) 
CD34   Cluster of differentiation-34; human endothelial/stem cell origin 
CD45   Cluster of differentiation-45; human hematopoietic antigen 
cDNA   Complementary deoxyribonucleic acid 
DAPI   4’,6-diamidino-2-phenylindole 
DMEM  Dulbecco’s modified eagle’s medium 
EBM2   Endothelial Basal Medium-2 
ECs    Endothelial cells 
FBS   Fetal bovine serum 
FLCs   Fetal liver cells 
GFAP   Glial fibrillary acidic protein 
Glut1    Glucose transporter-1 
HDMECs   Human dermal microvascular endothelial cells 
HemECs  Hemangioma endothelial cells 
HemSCs   Hemangioma-derived stem cells 
IH    Infantile hemangioma 
IL-6   Interleukin 6 
MCP-1  Monocyte chemoattractant protein-1 
xi 
 
mRNA   Messenger ribonucleic acid 
mTOR   mammalian target of rapamycin  
NANOG  STranscription factor involved in embryonic stem cell renewal 
NKX3.2  NK3 Homeobox 2 
OCT4/POUF5  Octamer-binding transcription factor 4 
PBS   Phosphate-buffered saline 
PI3K   Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PPARγ2   Peroxisome proliferator-activated receptor gamma 2 
PDGF   Platelet-derived growth factor 
qRT-PCR   Quantitative reverse transcription polymerase chain reaction 
RNA   Ribonucleic acid 
siRNA   Small interfering-RNA (silencing RNA) 
SOX2   SRY (Sex Determining Region Y)-Box 2 
SOX9   SRY (Sex Determining Region Y)-Box 9 
SP7   Osterix 
TBX2   T-box 2 
TGF-β   Transforming growth factor-beta 
TUBB3  Tubulin beta-3 chain 
uPAR    urokinase-type plasminogen activator receptor  
VE-cadherin  Vascular endothelial-cadherin 
VEGF    Vascular endothelial growth factor 
vWF   Von Willebrand factor 
α-SMA  Alpha-smooth muscle actin 
1 
 
 
 
Chapter 1 
1 INTRODUCTION  
1.1     Infantile Hemangioma 
   Infantile hemangioma, a benign tumour of vascular endothelial cells, is the most 
common type of childhood tumour appearing in 1 out of every 100 newborns.
1, 2
  Hemangiomas 
exhibit a strong predilection for the head and neck regions, which account for at least 60% of all 
lesions.
3-5
  They present more frequently in females than males, and are more prevalent in 
premature and Caucasian babies.
6, 7
  Uniquely, hemangiomas are characterized by distinct phases 
of proliferation and regression.
8-10
  Typically, a red patch arises within the first few weeks of life.  
Following formation of the initial lesion, the tumour progresses rapidly into the first phase: the 
proliferative phase. On average, proliferation perseveres for a period of 1 year during which 
masses of endothelial cells (EC) without defined vascular architecture is observed.
11
  At the age 
of approximately 1 year, the tumour enters the slow involuting phase, which may last between 1 
and 5 years. During this stage, changes are observed solely at the cellular level where EC 
hyperplasia is reduced and mature vessels become distinct.
8
  The final stage of this tumour is 
known as the involuted phase. This stage is typically reached by the age of 5–8, and is 
characterized by regression of the tumour due to the replacement of blood vessels by fibrofatty 
tissue.
10, 12
  No other vascular tumours demonstrate this type of life-cycle pattern, and as such 
this natural progression is utilized clinically to classify and diagnose IH.   
 
1.1.1  Clinical features of hemangioma  
   Hemangiomas are classified based on their anatomical location and histological properties.  
Slightly elevated lesions situated on the epidermis that appear red or purple in color are classified 
as superficial hemangiomas.
13
  Lesions located beneath the skin and within internal organs have 
often been referred to as deep hemangiomas. 
8, 13
  Categorizations of the vascular tumours as 
localized, segmental, indeterminate and multifocal lesions have also been proposed. 
3
  Further 
vocabulary used to describe morphological features of hemangiomas include strawberry, 
capillary, port-wine, cavernous, capillary-cavernous, and lymphangiohemangioma. 
11, 14, 15
  Due 
to the variability in nomenclature that is used to describe hemangiomas, misdiagnoses of 
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vascular tumours as malformation and vice versa is quite common.
14
  A landmark study by 
Mulliken and Glowacki
11
 established proper classification of IH based on the cellular and the 
histological features.  Their work demonstrated hyperplasia in hemangiomas but not vascular 
malformations. 
   Currently, the most accurate diagnostic confirmation of hemangiomas is achieved by staining 
biopsy specimens for Glucose transporter-1 (Glut-1).
5, 16
  Glut-1 is a member of a large 
transporter protein family, which is most commonly associated with erythrocytes.
17, 18
  In ECs, 
Glut-1 is noted to be expressed at the blood–brain/retinal-barrier and in the placenta 17-19  A 
large-scale study conducted by North et al. (2001) 
20
established the unique immunoreactivity of 
endothelial Glut-1 in hemangioma specimens, which was not observed in normal skin or other 
vascular anomalies including malformations.  
 
1.1.2  Current therapies for hemangioma  
   Approximately 20% of hemangiomas develop in areas that may cause serious and life-
threatening complications.
21
  These lesions frequently result in vision and airway obstruction in 
the infant.  Internal bleeding, ulceration, and congestive heart failure are also complications of 
hemangiomas obstructing internal organs.
5
  Most commonly, corticosteroids are administered to 
treat hemangiomas, however only 30% exhibit accelerated regression with this treatment.
9
  In 
addition, corticosteroid therapy has been noted to cause severe adverse effects in children, 
including growth retardation, immunosuppression and edema.
22
      
 
   Recently, propranolol was serendipitously found to be an effective treatment for IH with higher 
efficacy when compared to corticosteroid use.
23, 24
  Propranolol is a non-selective β-adrenergic 
receptor antagonist, yet its mechanism of therapeutic effect is currently unknown.  It is suggested 
to act on the pericytes surrounding capillaries that cause vasoconstriction (reviewed in
25
).  
Despite remarkable efficacy of propranolol,
24
 there are some adverse effects, which include sleep 
disturbances, acrocyanosis, hypotension, and hypoglycemia.
24, 26, 27
  Another concerning finding 
from a number studies is that some IHs regrow upon cessation of propranolol treatment, in as 
many as 20% of the cases.
28, 29
  While current therapies offer effective elimination of the tumour 
in some cases, the plausible side effects from their use cause great concerns for the health and 
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wellbeing of the children affected.  Further understanding of the cellular and molecular basis of 
hemangiomas is necessary to prevent complications and properly treat the tumour.   
 
1.1.3  Etiology of hemangiomas  
   Several hypotheses exist on the etiology of hemangiomas.  Two main ones include the extrinsic 
and the intrinsic hypotheses.  The extrinsic hypothesis suggests that the tumour 
microenvironment regulates hemangioma-genesis, whereby a signal imbalance in the tissue 
adjacent to the lesion contributes to the proliferation and progression of the tumour.
30
  For 
example, increased angiogenic factor expression (basic fibroblast growth factor, vascular 
endothelial growth factor) and hyperplasia in the epidermis overlaying proliferating-phase  
hemangioma have been reported.
30
  However, whether the primary signal imbalance originates 
from the microenvironment or the tumour itself is not fully clear. 
   Conversely, the intrinsic theory entails that a somatic mutation in one or more genes 
controlling EC proliferation is responsible for the tumour formation.   Examination of molecular 
markers expressed in situ and in cultured IH cells has granted insight to the possible origin and 
mechanism of IH pathogenesis.  Studies have shown that IH specimens express immature cell 
markers in addition to fully differentiated EC markers.
31, 32
  Further study of expression patterns 
of cultured IH-derived endothelial cells (hemEC) has revealed upregulated GLUT-1, and 
vascular endothelial growth factor (VEGF).
31, 32
  As previously mentioned, GLUT-1 is a 
particularly useful cell surface marker for the diagnosis of these lesions.  The similar pattern of 
Glut-1 expression observed throughout various stages of hemangiomas and placenta insinuates 
the possibility of a connection between the two, especially when it comes to the origin of the 
tumour.
18
  Cumulatively, the intrinsic hypothesis suggests that the ECs in hemangiomas originate 
from a single stem/progenitor cell and therefore implies that the cells are clonal in nature.  The 
potential placental origin of these stem/progenitor cells is strengthened by the evidence showing 
that disturbances in the microenvironment, such as transcervical chorionic villus sampling 
(CVS), increases the incidence of infantile hemangioma.
33, 34
  It is supposed that the invasive 
procedure causes intravascular dislodgment of placental cells, which enter the circulation and 
embolize to the developing fetus. 
35-37
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   The working hypothesis of our laboratory is a combination of the intrinsic and extrinsic 
hypotheses.  We have shown IH to arise from multipotential stem cells termed hemSCs.
16
  
HemSCs, isolated based on expression of stem cell antigen CD133, form GLUT-1 positive 
microvessels in immunodeficient mice. These GLUT-1 positive vessels are later replaced by 
human adipocytes, thus recapitulating the natural stages of human IH.  A schematic depicting our 
working model on the origin of hemangiomas is provided in Figure 1.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Current theories of hemangioma etiology. Schematic diagram illustrating   
the theory behind the evolution of infantile hemangioma.  A combination of genetic and 
environmental factors cause CD133+ cells to undergo clonal expansion and to give rise to 
all of the cellular constituents within the tumour. (EC: endothelial cell; EPC: endothelial 
progenitor cell; SC: stem cell; SMA: smooth muscle actin; RBC: red blood cell) 
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1.1.4  Aberrant signaling pathways in hemangioma  
   Several signaling pathways have been implicated in IH pathogenesis.  Studies have focused 
particularly on the VEGF (vascular endothelial growth factor A) pathway. VEGF-A is a 
regulator of angiogenesis and vasculogenesis.
38
  VEGF-A has been shown to be present at higher 
levels during the proliferating phase of hemangioma growth as compared to the involuting 
phase.
32, 39-42
  Serum levels of VEGF-A also decrease following systemic steroid therapy.
43
  The 
high expression of VEGF might be related to hypoxia, as increased hypoxia inducible factor-1α 
(HIF-1α) stabilization was reported in patients with proliferating IH. 40 A recent study 
demonstrated that silencing the expression of VEGF-A or VEGF receptor 1 (VEGFR-1) in 
hemSCs by short hairpin RNA (shRNA) was sufficient to block blood vessel formation when the 
cells were injected in immunodeficient mice. 
41, 44
 
   The angiopoietin-Tie2 pathway has also been suggested to contribute to IH pathogenesis.  
Angiopoietin-1 (ANGPT1) and angiopoietin-2 (ANGPT2) signal through TIE1/2 to regulate 
distinct steps in vascular remodeling, vessel maturation and vascular inflammation.
45, 46
  Tie2 
mRNA and protein have been shown to be up-regulated in hemECs relative to normal 
endothelial cells.
47
  Calicchio and colleagues also found ANGP2 mRNA significantly increased 
in hemangioma endothelium relative to normal placental vessels.
48
  Although robust levels of 
mRNA and protein have been noted in hemangiomas and hemangioma-derived cells, 
confirmatory studies in animal models as well as mechanistic studies are needed to clearly define 
the role of angiopoietins and TIE2 in the growth and involution of IH. 
   The Notch pathway has also been recently implicated in hemangioma-genesis. This 
evolutionarily conserved signaling system regulates cell-fate determination during development 
and in stem cells. In the vascular system, interaction of Notch receptors (Notch1 to Notch4) with 
their ligands (Delta-like 1, Delta-like 3, Delta-like 4, Jagged-1and Jagged-2) regulates the 
specification of endothelial cells into arterial and venous phenotypes during development.
49
  
JAGGED1 has been reported to be expressed in IH endothelium.
48, 50
  In addition, Notch3 is 
expressed by hemSCs and becomes prominently expressed in the perivascular cells in the 
involuting phase.
50
  Thus, it seems that signaling between hemangioma endothelial cells and 
pericytes is mediated by the Notch pathway. 
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   More recently, the mammalian target of rapamycin (mTOR) signaling pathway was shown to 
be involved in hemangioma pathogenesis. mTOR is a major signal convergence protein that 
transduces signals from the extracellular matrix to corresponding changes in basic intracellular 
processes including proliferation, protein synthesis and autophagy.
51
  Recent studies have found 
that rapamycin (inhibitor of mTOR) inhibits the proliferation and the self-renewal activity of the 
hemSCs.  It prevented hemSCs, either alone or combined with endothelial cells, from forming 
blood vessels in vivo. 
52
 Beside its anti-vasculogenic effect on hemSCs, rapamycin has anti-
angiogenic effect on the hemECs, suppressing their proliferation.  
   The renin-angiotensin system has recently been suggested to play a role in IH pathogenesis as 
well as in the response to propranolol.
53
  Specifically, it was suggested that angiotensin II could 
drive proliferation of endothelial progenitor cells into mitotically active cells that characterize 
IH.
54
  However, this notion is based mostly on immunohistochemical staining of IH specimens 
and support for this theory from in vivo studies is lacking.  Poor effect of the ACE inhibitor 
captopril on IH also discounts this signaling pathway as being involved in hemangioma 
pathogenesis.
55
 
   Various other factors have also been found to be differentially expressed in the proliferating 
phases of IH but their role is less defined. These include monocyte chemoattractant protein-1 
(MCP-1),
56
 interleukin 6 (IL-6) and urokinase-type plasminogen activator receptor (uPAR) 
42
 
and insulin-like growth factor 2 (IGF-2).
57, 58
  The cell adhesion molecule E-selectin, normally 
only expressed in inflamed endothelium, is strongly expressed on vessels in proliferating phase 
IH.
59
  E-selectin is also expressed by proliferating phase hemECs and may mediate interactions 
with hemSCs. 
60
  While many pathways have been shown to be aberrantly expressed/active in 
IH, no single defining signaling mechanism regulating hemSC differentiation or hemEC 
proliferation has yet been established.  
 
1.1.5  Stem cells in hemangioma 
   We and others have found IH specimens to be immunoreactive to embryonic stem cell (ES) 
markers, such as OCT4, Nanog, Sox2, c-myc, SALL4. 
31, 61-63
  These markers are associated with 
pluripotency due to their expression and activity coinciding with the ability of ES to differentiate 
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into all three germ layers.
64-68
  Interestingly, the expression of ES markers in IH is localized to 
both the interstitium and the endothelium, whereas CD133 expression is restricted to the 
endothelium.  Cells isolated based on CD133-expression (hemSCs) exhibit competence to 
differentiate into cells of multiple lineages in vitro, and repeated endothelial differentiation upon 
serial implantation in mice.
16
  HemSCs exhibit fibroblastic morphology in culture and share cell 
surface marker expression with bone marrow-derived mesodermal/mesenchymal stem cells 
including CD90, neuropilin-1 and VEGF receptors.  Since hemSCs were isolated based on the 
expression of CD133 (a marker restricted to the endothelium by immunostaining), it is plausible 
that upon culture, these cells revert to their parental mesodermal stem cell state.   
   Recently, Bischoff et al. (2015) have demonstrated the GLUT1-positive endothelial cells lining 
the blood vessels of IH, to have properties of mesenchymal/mesodermal stem cells.
69
  Upon 
isolation and in vitro culture, these cells reverted to a mesenchymal stem cell phenotype by 
upregulating CD90, platelet-derived growth factor receptor-β (PDGFRβ), and neural glial 
antigen-2 (NG2).  Notably, the GLUT1-negative population retained a stable endothelial 
phenotype in culture.  GLUT1-positive cells also displayed robust clonogenic capacity, 
suggesting that these cells possibly derive from a mesenchymal/mesodermal stem cell.  It is 
important to note that hemSC population demonstrated to recapitulate IH upon transplant in mice 
were isolated purely on the basis of being CD133-positive, and therefore likely included both 
GLUT1 positive and negative populations.   
 
   The perivascular cells surrounding the nascent vessels in the proliferative phase hemangiomas 
express the pericyte markers α-smooth muscle actin (α-SMA), NG2, PDGFRβ, calponin, and 
smooth muscle myosin heavy chain.
70
  Pericytes are abundant in the proliferating phase and 
appear to undergo a maturation process concurrently with the endothelial cells. 71  Recently, 
Yuan et al. isolated PDGFRβ-positive cells and showed expression of CD105, CD90, vimentin, 
and CD133.  These cells showcased multi-lineage differentiation in vitro into adipocytes, 
osteocytes, and chondrocytes.  Upon transplant, these PDGFR-B+ pericytes underwent 
adipogenic differentiation.  Thus, it is possible that both GLUT1-positive ECs and PDGFRβ-
positive pericytes are derived from CD133+ population isolated in our previous study.     
   We have shown that hemSCs differentiate into mesenchymal (adipocyte, osteoblast, and 
chondrocyte), endothelial, and neuroglial lineages in culture.
16
  Notably, one lineage for which 
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that hemSCs have not been fully characterized is the hematopoietic lineage.  This is noteworthy 
as studies have shown IH lesions to be comprised of a significant proportion of cells with 
myeloid lineage markers.  Ritter et al. comprehensively demonstrated IH specimens to stain 
positive for CD45, CD14, CD15 and CD83.
72
  Significantly, the dendritic cell marker CD83 and 
the myeloid marker CD15 were found to be expressed in IH endothelium, and decreased during 
involution of the tumour. 
72
  In addition, Glut1 and CD32 (which are both present in the placenta 
as well as on myeloid cells) was shown to be co-expressed with CD83 and CD14 positive 
endothelium, respectively.  This suggests that the former two markers may indeed be indicative 
of a myeloid cell lineage as opposed to a placental origin.   
   Additionally, mast cells are present in IH.
73, 74
 Their number predominates in the early to 
middle involuting phase, whereas lower numbers are seen in the proliferative and the involuted 
phases.
32
 This difference has led to the hypothesis that mast cells play a role in the regression of 
IH. Moreover, it has recently been demonstrated that mast cells are present in comparable 
numbers in various skin tumours, including basal cell carcinoma, squamous cell carcinoma, 
melanomas and nevi.
75
  Thus, the unique role of mast cells in IH requires further study. 
   One group has observed IH biopsies to generate enucleated erythrocytes in vitro, however they 
failed to characterize which cellular constituents from the explants were responsible for the 
demonstrated erythropoiesis. 
76
  Yet, their work proposes an interesting link between the 
endothelial cell derivation seen by Boscolo et al.
44
 and the myeloid markers seen by Ritter et al.
72
   
Historically, a common precursor to endothelial and hematopoietic lineages has been debated for 
many years.  The concept of a hemangioblast, a mesodermal precursor for the hematopoietic and 
endothelial lineages, was first suggested in the early 20
th
 century by Sabin and Murray (reviewed 
in 
77
), due to the proximity of the hematopoietic and endothelial lineage development within the 
blood islands.  Evidence for the hemangioblast has since been found in vitro, where groups have 
identified embryoid bodies developed from human ES contain a unique population of precursor 
cells for both lineages.  These precursor cells formed blast-like colonies which were shown to 
have similar expression patterns for genes common to both hematopoietic and endothelial cells, 
including CD34, Tal1/SCL, and flk-1 (VEGFR1).
78
  These blast colony-forming cells (BL-
CFCs) generated both hematopoietic and endothelial cell precursors, while cultured in growth 
factors supporting the differentiation of both lineages.
77
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   Similarly, evidence for haemogenic endothelium during embryonic development has been 
demonstrated at the aorta-gonad-mesophrenos (AGM) stage of hematopoietic activity.  It is 
interesting that IH typically emerges at a temporally determined stage.  Its post-natal appearance 
may correspond to the hematopoietic transition from the fetal liver to the bone marrow.  IH has 
been reported in the infant liver.  In fact, with respect to visceral hemangioma, liver is the most 
commonly involved internal organ, followed by lungs, brain, and intestine.
79
  If we contemplate 
the possibility that hemSCs in IH originate from a signaling alteration or mutation at the 
hemangioblast level, or a switch in mesoderm signaling to haemogenic endothelium, this may 
explain the mesenchymal, endothelial, and hematopoietic potential of hemSCs in IH.   
 
1.2    Transcription factor T-box 2 
   Recent gene expression profile has revealed a number of genes altered in hemangioma 
specimens which may be responsible for the underlying pathogenesis.  One gene identified was 
transcription factor TBX2 which is significantly downregulated upon IH involution.
57
  Our 
laboratory has shown that knockdown of TBX2 in hemSCs impedes adipogenic differentiation.
80
  
This suggests that TBX2 may have a role in the progression of the tumour.  However, the precise 
role and underlying mechanisms are not known.  
   T-box 2 belongs to the T-box family of transcription factors that play a critical role during 
development.  Only a few mutations in T-box genes are known, but all have drastic effects on 
development, including a targeted mutation in mice causing an embryonic lethal phenotype, and 
two human T-box gene mutations that results in developmental syndromes (reviewed in 
81
).      
T-box family members are characterized by a highly conserved region of approximately 200 
amino acid residues corresponding to the DNA binding domain known as the T-box.  The 
prototype of the T-box family, Brachyury or T, is the most extensively studied and has been used 
to elucidate the structure and function of other family members.  All members characterized to 
date have been shown to bind to the core sequence GGTGTGA, referred to as the T-element, as a 
monomer.
82
  Although all T-box proteins recognize similar DNA sequences, evidence suggests 
they regulate different target genes which may be dependent on the promoter context and co-
factors.
83-85
  Tbx2 belongs to the Tbx2 subfamily of T-box transcription factors, which include 
Tbx3, Tbx4, and Tbx5.
86, 87
  Whereas TBX2 is most closely related to TBX3, TBX4 and TBX5 
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are more closely related to each other.  In the mouse, Tbx2 is located on chromosome 11
87
 while 
in humans, TBX2 has been mapped to chromosome 17q23.
88
 The T-box domain of the human 
TBX2 shares 90% DNA and 96% peptide sequence homology with its mouse counterpart.
89
  
   Unlike most members of the T-box family that function as transcription activators, Tbx2 is a 
potent repressor of its target genes. 
90, 91
  Paxton et al.
92
 identified two separate transcription 
repression domains; a novel amino-terminal repression domain and confirmed the presence of a 
carboxy-terminal repression domain identified in an earlier study. 
92, 93
  A weak activation 
domain was also located within the T-box and indeed Tbx2 was capable of activating a promoter 
containing multiple T-elements. 
92
 The presence of both activation and repression domains 
within the Tbx2 protein suggests multiple but specific roles for this transcription factor, 
depending on the cellular context or species. 
 
1.2.1  Known functional roles of T-box 2 in development 
   Tbx2 is expressed in the mouse heart, lung, kidney, ovary and in cells of melanocyte lineage.
87, 
90
  In humans, it is expressed in a wide variety of tissues including kidney, lung, placenta, ovary, 
prostate, spleen, testis, breast, heart, thymus, intestine, and polymorphonucleocytes. 
88, 89
 
Targeted mutagenesis has shown that heterozygous mutants are normal while homozygous 
mutants die of cardiac insufficiency between 10.5 and 14.5 days post coitum (reviewed in 
94
). 
Human TBX2 has not yet been linked to any known genetic syndrome but has been implicated in 
several developmental processes, such as coordinating cell fate, patterning, and morphogenesis 
of a wide range of tissues and organs including limbs, kidneys, lungs, mammary glands, heart, 
and craniofacial structures (see reviews, 
94, 95
).   
   During cardiogenesis, Tbx2 is important in proliferation and patterning of the developing 
heart.
96
  At around 8 and 10 days post coitum, Tbx2 is detected in the nonchamber myocardium 
of the developing mouse heart, which is consistent with Tbx2 expression patterns during chick 
heart development.
97, 98
  In vitro reporter assays and transgenic mice studies have shown that 
during non-chamber formation, Tbx2 represses the transcription of natriuretic peptide A, and 
connexins (Cx) 40 and 43 thus regulating the formation of the multi-chambered heart.
97, 98
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   Tbx2 has been shown to regulate expression of the genes encoding collagen type 1a and Cx43, 
which are both crucial in bone formation. Gap junctions, composed of Cx protein subunits 
connect the cytoplasm of adjacent osteocytes and are, therefore, important in cell–cell 
communication.  Cx43 is the predominant gap junction protein in bone and its tightly regulated 
temporal expression pattern plays a critical role in normal ossification and osteoblast function.
99
  
Tbx2 and Cx43 are co-expressed in osteogenic progenitors and osteoblasts, suggesting that Cx43 
may be a potential Tbx2 target gene in bone.
100
  Osteosarcoma cell lines transfected with anti-
sense Tbx2 have demonstrated that inhibition of Tbx2 results in a marked increase in Cx43 
expression.
100, 101
 
   Tbx2, Tbx3, Tbx4, and Tbx5 are expressed in developing mouse limbs either at the time of 
limb field specification, during limb bud outgrowth, or both.
102, 103
  A study by Suzuki et al.,
104
 
suggests that Tbx2 and Tbx3 play an important role as a positive regulator of Shh expression 
within the posterior limb bud. A recent study also suggests Tbx2 is responsible for limiting Shh 
expression to the margins of the limb bud.
105
    
   Both TBX2/Tbx2 and TBX3/Tbx3 have been implicated in mammary gland development in 
mice and humans. Both factors are expressed in the developing mouse mammary gland, where 
they are expressed in specific spatiotemporal patterns in the mesodermal and epithelial cell 
layers (reviewed in 
106
).  During the emergence of the mouse mammary gland, Tbx2 is expressed 
in the underlying mesodermal cells, while Tbx3 is expressed only in the epithelial cells.  
Interactions between the epithelial and mesodermal cell layers are known to govern induction 
and development of the mammary glands (reviewed in 
107, 108
).   
    Finally, Tbx2 expression has been observed in several melanocyte and melanoma cell lines but 
not in premelanoblast cells.
90
  Studies have also implicated Tbx2 in the patterning and 
development of the hypothalamus,
109
 and the mammalian embryonic eye (reviewed in 
110
).   
 
1.2.2  Known regulators of T-box 2  
   While the mechanisms directly regulating TBX2 are not comprehensively characterized, there 
is evidence suggesting a number of pathways involved in cellular processes contributing to 
embryonic development and tumourigenesis, are modulators of TBX2 expression.   
12 
 
 
 
   Wnt signaling has been suggested to activate TBX2 during embryonic development and 
cancer.  TBX2 is activated by bone morphogenetic protein (Bmp) 2 and bone morphogenetic 
protein 4 during heart patterning, downstream of the Wnt/ β-catenin pathway.111  Additionally, 
inhibition of β-catenin degradation induced TBX2 mRNA and protein levels, in pancreatic 
cancer cells.
112
 
   Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling has been suggested as a 
modulator of TBX2, as adrenal carcinoma cells treated with a PI3K inhibitor demonstrated 
decreased TBX2 mRNA levels.
113
  PI3K is associated with upregulated VEGFR-2 signaling in 
tumourigenic cells,
114
  and can play a crucial role in cancer progression by co-operating with cell 
proliferation signals.
115
  However, a mechanistic detail as to how is may interact with the TBX2 
promoter has not yet been described.   
  TBX2 is also up-regulated by the protein kinase C (PKC) signaling pathway.
116
  The latter was 
upregulated in normal human fibroblasts by the tumour promoting agent TPA.  In response, PKC 
signaling phosphorylates histone H3 leading to chromatin remodelling and recruitment of 
transcription factor specificity protein 1 (Sp1) to the TBX2 promoter and subsequent activation 
of TBX2 mRNA expression. 
   The transforming growth factor β1 (TGF-β1) pathway is critical for a number of cellular 
processes including cell differentiation, proliferation, apoptosis, and during the immune response 
(reviewed in 
117
).  This multi-functional cytokine mainly exerts its effects by binding and 
activating the TGFβ receptors I and II, which initiate a cascade of signaling events frequently 
involving Smad proteins and co-factors (the canonical pathway) but which can also be Smad-
independent (non-canonical).
118
  Recently, TBX2 mRNA was found to be upregulated following 
TGF-β treatment in mammary epithelial cells, and furthermore shown to be a driver of epithelial 
to mesenchymal transition (EMT) in breast cancer.
119
  Contrarily, a positive relationship between 
TGFβ and TBX2 has been suggested, whereby the anti-proliferative effect of TGFβ on B16 
melanoma cells was rescued by Tbx2 overexpression.
120
  TGF-β is also known to be upstream of 
TBX2 in cardiac development
121
 and melanoma cell development.
122
   Furthermore, it is 
upregulated upon involution in IH.
39
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1.2.3  Known functional roles of T-box 2 in tumourigenesis 
   In addition to its key function in development, evidence suggests Tbx2 plays a role in 
carcinogenesis.  For example, Tbx2 and the closely related factor Tbx3, have been implicated in 
cell cycle regulation and their expression is upregulated in a number of cancers, including 
breast,
123, 124
 pancreatic,
125, 126
 melanoma,
127, 128
 liver,
129
 and bladder:
130
  
   Tbx2 and TBX3/Tbx3, as mentioned earlier, are involved in normal breast development and 
studies have shown that their altered expression may be important in the pathogenesis of breast 
cancer. TBX2 was shown to be amplified and overexpressed in a subset of breast cancer cell 
lines and primary tumours in BRCA1- and BRCA2-related breast tumours.
123, 131
  Both TBX2 
and TBX3 have also been associated with pancreatic cancer. While TBX2 was found to be 
overexpressed in 50% of 31 pancreatic cancer cell lines tested,
125
 TBX3 was shown to be 
upregulated in metastatic pancreatic endocrine neoplasms.
126
  Furthermore, both TBX2/Tbx2 and 
TBX3 are expressed in normal melanocytes and have been found to be strongly upregulated in a 
subset of melanoma cell lines.
90, 127, 128
  
   A possible mechanism for how TBX2 and TBX3 may contribute toward the oncogenic process 
is suggested by studies which have shown that they are both able to function as immortalizing 
genes that enable the cells to bypass senescence.
131
  The main mediators of senescence are the 
cyclin dependent kinase inhibitors (Cdkis), p21WAF1/CIP1/SDII  (referred to as p21) and 
p16INK4a, with p21 thought to be necessary for initiating the senescence-like growth arrest 
while p16INK4a is required for maintenance of this state.
132
  The induction of p21 appears to be 
largely p53- dependent and the Cdki, p19ARF, has also been shown to initiate a senescent-like 
growth arrest by stabilizing p53 protein levels.
133
  Using two different cell culture models of 
senescence, investigators have shown that both Tbx2 and Tbx3 can behave as immortalizing 
genes by preventing senescence.
131, 134, 135
  In these studies, TBX2 and TBX3 were shown to 
prevent senescence by a mechanism involving their ability to transcriptionally repress p19ARF 
(mouse homologue of the human p14ARF) and p21.  Whether TBX2 and TBX3 also contribute 
to tumour progression via other mechanism(s) is poorly understood. 
   In summary, Tbx2 has been implicated in several developmental processes, is emerging as a 
key regulator of the cell cycle, and has been implicated in several cancers. However, very little is 
14 
 
 
 
known about the biochemical pathways regulating the expression and activity of Tbx2; there is 
limited information regarding its target genes.  Based on its demonstrated roles coordinating cell 
fate during development and promoting oncogenesis, we believe it presents as a strong candidate 
for contributing towards hemangioma pathogenesis.   
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Chapter 2 
2 PURPOSE AND OBJECTIVES OF THESIS  
2.1    Purpose of thesis  
While the precise role of TBX2 in hemangioma remains elusive, up-regulated expression of this 
transcription factor in the proliferative phase suggests a potential role in tumour progression.  
Increased expression of TBX2 in hemangiomas has been identified by Ritter and colleagues in 
the proliferative stage.
57
  However, the level decreases during the involution phase, suggesting 
that TBX2 is a regulator of initiation and/or growth of hemangioma.  The purpose of my study is 
to investigate the role of transcription factor T-box 2 in modulating the differentiation 
competence of hemSCs (Figure 2.1).  I hypothesize that high TBX2 maintains a differentiation 
competent state in hemangioma-derived stem cells by modulating cell pluripotency and 
proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  Stem cell derived cellular constituents of infantile hemangioma. 
Schematic diagram illustrating the potential role of transcription factor T-box 2(TBX2)   
in modulating the differentiation of hemSCs in infantile hemangioma to give rise to the  
cellular constituents seen within the tumour. 
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2.2    Objectives of thesis  
My studies focused on the characterization of TBX2 expressing cells in hemangiomas.  I sought 
to study the effect of TBX2 in hemangioma-derived cells and investigate the TBX2 signaling 
pathway (Figure 2.2).  My specific objectives were:  
I. Localization of TBX2 expressing cells in hemangioma specimens and 
characterization of T-box family expression in hemangioma cell culture.   
II. Determination if inhibition of TBX2 leads to loss of differentiation ability in hemSCs. 
III. Investigation of the signaling network regulated by TBX2 in hemSCs through 
identifying upstream modulators and downstream targets of TBX2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Mechanisms regulating differentiation-competence of hemSCs. 
Schematic diagram illustrating the signaling pathways of interest within this study that  
may regulate the differentiation-competence of hemSCs via transcription factor TBX2.  
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Chapter 3 
3  MATERIALS AND METHODS  
3.1   Infantile hemangioma specimens and immunostaining 
   All studies were conducted following approval by the Research Ethics Board at Western 
University, London, Ontario, Canada. Paraffin-embedded IH specimens were obtained from the 
Department of Pathology Archives at the London Health Sciences Centre (LHSC, London 
Ontario, Canada). The proliferating phase was confirmed through medical history, physical 
examination, and histological analysis of densely packed capillaries. In addition, all hemangioma 
sections were immunostained with Glut1 to confirm diagnosis. Tissue sections were 
deparaffinized, hydrated, and subjected to antigen retrieval using Tris/EDTA buffer (10 mM 
Trizma-base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) in 2100 Retriever (Electron Microscopy 
Sciences, Hatfield, PA).  Slides were incubated with rabbit anti-TBX2 antibody (1:50, 
HPA008586, Sigma-Aldrich) and mouse anti-human CD31 (1:100, M0823, Dako Canada, 
Mississauga, ON); rabbit alpha-smooth muscle actin (1:200, ab5694, Abcam Plc); mouse anti-
OCT4 (1:200, MAB17531, R&D Systems) for 1 hour at room temperature; Fluorescein- or texas 
red-conjugated secondary antibodies (Vector Laboratories, Burlington, ON) were used for 
detection. Slides were counterstained with DAPI (Vector Laboratories). Images were taken using 
the Olympus BX-51 microscope (Olympus Canada In., Richmond Hill, ON) equipped with a 
Spot Pursuit digital camera (SPOT Imaging Solutions, Sterling Heights, MI).  Positive controls 
for staining experiments comprised of human early gestation placenta (20-25 weeks) specimens; 
malignant melanoma specimens; lung carcinoma specimens; renal cell carcinoma specimens.  
Negative controls for staining experiments were conducted with human hemangioblastoma 
specimens; incubations of hemangioma specimens without the primary antibody added to the 
sample (to indicate if any non-specific binding or false positives may be due to non-specific 
binding of the secondary antibody). 
 
 
 
18 
 
 
 
3.2  Infantile hemangioma cell culture 
   Proliferating IH-derived CD133+ cells (hemSCs) were provided by Dr. Joyce Bischoff 
(Children’s Hospital Boston, Boston, MA). We have previously characterized these cells through 
qRT-PCR, immunostaining, and cellular activity assays.
16
  Freshly isolated human bone marrow-
mesenchymal progenitor cells (bm-MPCs; isolated from bone marrow mononuclear 
preparations; 2M-125B, Lonza Inc., Walkersville, MD) were used as normal stem/progenitor 
controls.  CD133-positive human fetal liver cells were obtained from DV Biologics (Yorba 
Linda, CA).  All cells were cultured in complete EBM2 media (Lonza, Walkersville, MD) 
supplemented with 20% fetal bovine serum (Lonza), EGM-2 SingleQuots (CC-4176, Lonza Inc.) 
and 1X antibiotic antimycotic media (PSF; Life Technologies). Cells were cultured under 
identical conditions and experiments were performed with a minimum of 2 biological replicates 
and 3 technical replicates.  Throughout the results sections, biological replicates (hemSC 
preparations isolated from different patient tumours) are represented as “N”; experimental 
replicates (repetitions of the same experiment on different dates) are represented as “n”.  Within 
each cell culture experimental set, a minimum of 3 technical replicates were included (ie. 3 
technical replicates per “n”).  Furthermore, analysis via RT-PCR (Section 3.6) included 3 
technical replicates per RNA sample.   
 
3.3  Differentiation assays 
   To study multilineage differentiation, cells were treated with induction media for 14 days. 
Mesenchymal differentiation of the cells was carried out with adipogenic media (StemPro 
Adipogenesis Differentiation Kit, ThermoFischer Scientific, A1007001), osteogenic media 
(StemPro Osteogenesis Differentiation Kit, ThermoFischer Scientific, A1007201), and 
chondrogenic media (StemPro Chondrogenesis Differentiation Kit, ThermoFischer Scientific, 
A1007101).  Endothelial cell differentiation was carried out in serum-free medium containing 
VEGF-B (EBM-2, 1× insulin-transferrin-selenium, 1:5000 linoleic acid–albumin, 1 μM 
dexamethasone, 60 μM ascorbic acid–2–phosphate, 10 ng/mL VEGF-B).  For neuroglial 
differentiation, cells were exposed to initiating medium (DMEM/10% FBS, 1 mM β-
mercaptoethanol) for 24 hours. Induction medium (DMEM, 0.1 μM dexamethasone, 0.25 μg/mL 
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insulin, 5 μM cAMP, 0.5 mM isobutylmethylxanthine, 5 μM trans-retinoic acid, 0.25 mM l-
glutamine, and 25 ng/mL nerve growth factor) was then used for 14 days.  Hematopoietic 
activity was assessed in MethoCult medium (StemCell Technologies) at 10
3
, 10
4
, 10
5
, and 10
6
 
cells per 35-mm dish. Mesenchymal differentiation was assessed by upregulation of CEBPα and 
PPARγ gene expression for adipogenesis, SP7/Osterix for osteogenesis, NKX3.2 and SOX9 for 
chondrogenesis, TUBB3 and GFAP for neuroglial; CD31, VE-cadherin and VWF for endothelial 
differentiation; CD45, CD34 and c-kit for hematopoietic lineage differentiation.  Morphological 
changes were also observed and recorded.  Images were taken with an Olympus CK2 using 
SPOT Advanced 3.5.9 software (Diagnostic Instruments Inc.) and a ×20/0.45 objective lens. 
 
3.4  Cellular Transfection with siRNA 
   Cells were grown in complete EBM2 media. The day prior to the transfections, the media was 
replaced with antibiotic/antimycotic-free media. Twenty-four hours later, the cells were 
trypsinized and then transfected with either TBX2 siRNA (sc-38469) or control siRNA (sc-
37007) using electroporation (Neon® Transfection System, Life Technologies).  For siRNA 
transfections, we used the following protocol: 1400v, 20 ms, 2 pulses. Effective concentration of 
siRNA (both control and TBX2 siRNA) utilized was 50 µM (50 x 10−6 mol/L).  Knockdown 
efficiency was determined at 24 h, 48 h post-transfection or at day 7 using real time RT-PCR.  
This protocol was used to transfect hemSCs.   
 
3.5  Cell viability assays 
   Post-transfection, the growth of hemSCs was assayed by measuring total live cell number with 
Scepter 2.0 Automated Cell Counter (Millipore) for both control and TBX2 knockdown cultures.  
Viability was measured at 24 h, 48 h, 72 h and 7 days.  Transfection efficiency was confirmed at 
the time of cell count (following lysis and RNA isolation).   
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3.6  RNA isolation and qRT-PCR 
   RNA was isolated using either RNeasy Micro Plus Kit (Qiagen, Mississauga, CA), or 
SingleShot Cell Lysis Kit (172-5080, Bio-Rad Laboratories, Hercules, CA).  RNA was measured 
using Qubit RNA Broad Range Assay in a Qubit Fluorometer (Life Technologies). cDNA was 
then synthesized using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA).  All 
cellular differentiation and TBX2 pathway component gene expression was assessed by qRT-
PCR (Table 1).  Target gene mRNA data was normalized to β-actin (QT01680476, Qiagen). 
Pluripotency factor expression was also analyzed utilizing a human iPSC colony qBiomarker 
screening PCR array (337221 IPHS-001A, Qiagen), for which data was normalized to GAPDH.  
All qRT-PCR reactions consisted of 10 μL RT² SYBR Green FAST Mastermix (330602, 
Qiagen), 2 μL of both forward and reverse primers (at a 10 μM concentration), ~2 μL cDNA 
(volume adjusted for individual cDNA samples to constitute 300ng per PCR reaction), and 6 μL 
of H2O.  All reactions were performed for 40 cycles using the following temperature profiles: 
95°C for 2 minutes (initial denaturation); and 60°C for 30 seconds (annealing and extension).  
Data was analyzed by CFX Manager Software using normalized relative quantity (ΔCT; ΔΔCT) 
method with two housekeeping genes (β-actin and GAPDH).   
 
Table 1:  List of primers used 
Gene  Source (Catalogue ID) 
Β-actin 
CD31 
CD34 
CD45 
CD133 
C/EBPα 
CKIT 
COL1 
COL4 
Qiagen (QT01680476) 
Qiagen (QT00081172) 
Qiagen (QT00056497) 
Qiagen (QT02306717) 
Qiagen (QT00075586) 
Qiagen (QT00203357) 
Qiagen (QT00080409) 
Qiagen (QT00037793) 
Qiagen (QT00005250) 
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E-caderin 
DNMT3A 
DNMT3B 
DPPA4 
GLUT1 
GATA2 
GATA3 
GFAP 
LEFTY 
NANOG 
NKX3.2 
OCT4/POUF5 
p16ARF/p19/CDKN2A 
p21/CDKN1A 
PPARγ 
RUNX1 
SCL/TAL 
SOX2 
SOX9 
SP7/Osterix 
TBX2 
TBX3 
TBX4 
TBX5 
TUBB3 
VE-cadherin 
vWF 
ZFP42 
Qiagen (QT00080143) 
Qiagen (QT00090835) 
Qiagen (QT00032067) 
Qiagen (QT00046515) 
Qiagen (QT00068957) 
Qiagen (QT00045381) 
Qiagen (QT00095501) 
Qiagen (QT00081151) 
Qiagen (QT00037373) 
Qiagen (QT01025850) 
Qiagen (QT01079582) 
Qiagen (QT00210840) 
Qiagen (QT00089964) 
Qiagen (QT00062090) 
Qiagen (QT00029841) 
Qiagen (QT00026712) 
Qiagen (QT00012530) 
Qiagen (QT00237601) 
Qiagen (QT00001498) 
Qiagen (QT00213514) 
Qiagen (QT00091266) 
Qiagen (QT00022484) 
Qiagen (QT00024052) 
Qiagen (QT00056574) 
Qiagen (QT00083713) 
Qiagen (QT00013244) 
Qiagen (QT00051975) 
Qiagen (QT00051009) 
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3.7  Signaling network assays  
   To investigate potential upstream regulators of TBX2, I cultured hemSCs with the addition of 
exogenous pathway component agonists/antagonist to control media in a dose-dependent 
manner.  The investigated pathways were selected based on known regulators of TBX2.
136
  
Reagents and concentrations used are listed in Table 2.  The effective concentrations of these 
signaling pathway modulators were determined empirically in our laboratory.  Reagent 
concentrations were optimized for cell reponse, ie.  TGFβ1(240-B-010, R&D Systems) was 
added at concentrations 5ng/mL, 10ng/mL, 15ng/mL.  To confirm functional response of 
hemSCs to the treatments, we examined up-regulation of known downstream targets of 
treatments post-culture (ie. upregulation of collagen I and IV mRNA expression for TGFβ1 
treatment).    
Expression analysis for TBX2 mRNA was conducted at 24 h, 48 h, 72 h, and day 7 timepoints, 
following RNA isolation. 
 
Table 2: List of pathway component treatments used   
Reagent Target pathway Effective 
concentration 
Source 
Calmodulin 
dependent 
kinase inhibitor KN‐
93 
 
Chelerythrine 
chloride 
 
GW788388 
 
IWR-Endo 
 
PI-828 
 
PNU74654 
 
 
Microtubule-
dependent cell cycle 
events; calcium 
signal transduction 
 
PKC translocation; 
apoptosis 
 
TGF-β signalling 
 
Wnt signalling 
 
PI3K signalling 
 
Wnt-β catenin 
pathway 
 
500 nM 
 
 
 
 
700 nM 
 
 
10 nM 
 
10 μM 
 
2 μM 
 
20 μM 
 
 
Tocris Biosciences (1278) 
 
 
 
 
Cayman Chemicals (11314) 
 
 
R&D Systems (3264/10) 
 
Cayman Chemicals (13659‐10) 
 
R&D Systems (2814/1) 
 
R&D Systems (3534/10) 
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Rho Kinase Inhibitor 
VII 
 
Rac1 Inhibitor II 
 
 
TGF-β1 
  
TGF-β3 
 
Wnt Agonist 
Phosphorylation, 
dephosphorylation 
 
Phosphorylation, 
dephosphorylation 
 
TGF-β signalling 
 
TGF-β signalling 
 
Wnt signalling 
 
10 nM 
 
 
25 μM 
 
 
10 ng/mL 
 
10 ng/mL 
 
1 μM 
EMD Millipore (555556) 
 
 
EMD Millipore (553512) 
 
 
R&D Systems (240-B) 
 
R&D Systems (302-B2) 
 
Calbiochem EMD Millipore 
(853220‐52‐7) 
 
3.8  Statistical Analysis 
   Where appropriate, student’s unpaired t-tests or analysis of variance (ANOVA) were 
performed.  P values <0.05 were considered statistically significant.  The data were expressed as 
means ± standard deviation (SD) where student’s unpaired t-tests was performed, as a measure 
of data variability around the sample population mean; ± standard error of the mean (SEM) 
where ANOVA was performed, as a measure of precision for an estimated population mean. 
Following ANOVA, post-hoc analysis was conducted utilizing the Bonferroni procedure.   
Biological replicates (hemSC preparations isolated from different patient tumours) are 
represented as “N”; experimental replicates (repetitions of the same experiment on different 
dates) are represented as “n”.  Within each cell culture experimental set, a minimum of 3 
technical replicates were included (ie. 3 technical replicates per “n”).  Furthermore, analysis via 
RT-PCR (Section 3.6) included 3 technical replicates per RNA sample.   
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Chapter 4 
4  RESULTS 
4.1  TBX2 localization in hemangioma 
   I first screened for the expression of TBX2 in IH specimens by immunohistochemistry.  I 
confirmed that the specimens were hemangiomas by staining for Glut-1 (Figure 1-App).  I 
observed that proliferating hemangioma specimens were positive for TBX2, which was 
determined to be mostly nuclear as shown in merged images of TBX2 and DAPI (Figure 4.1A).  
TBX2 also co-localized with CD31 positivity, suggesting hemangioma endothelial cells 
expressed TBX2.  However, TBX2 expression was not restricted to the endothelium and showed 
positivity in both interstitial and perivascular cells.  To mark the perivascular cells, I performed 
staining for α-smooth muscle actin on serial sections (Figure 4.1B). These results confirm that 
TBX2 localizes to the perivascular cells as well the endothelium. However, as both TBX2 and α-
smooth muscle actin were from the same host and hence, definitive co-expression could not be 
determined on the same sections.   
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Figure 4.1: TBX2 is expressed in the nucleus of endothelial cells in infantile hemangioma. 
(A) Immunofluorescence (IF) staining Tbx2 (green).  
(B) IF staining alpha-smooth muscle actin (red). 
(C) IF imaging for endothelial marker CD31 (red) and TBX2 (green) 
[Scale bar represents 100µM; DAPI nuclear stain = blue].   
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4.2 Hemangioma stem cells express T-box transcription factors 
 
   I confirmed that TBX2 expression was retained in hemSCs, by immunofluorescent staining of 
CD133-positive hemangioma-derived cells in culture.  TBX2 was found to have primarily 
nuclear localization, however some cytoplasmic localization was also observed.  HemSC 
cultures of different primary patient origin appeared to exhibit unique nuclear/cytoplasmic TBX2 
localization as expected (Figure 4.2.1).  TBX2 mRNA analysis also showed robust expression in 
cultured primary hemSCs (Figure 4.2.2).  Cell preparations which exhibited higher levels of 
TBX2 mRNA expression tended to show mostly nuclear TBX2 localization. However, because 
of limited hemangioma cell preparations available, this was not pursued further with detailed 
analysis.   
   I furthermore characterized TBX2 in hemSCs relative to bone marrow-derived mesenchymal 
progenitor cells (bm-MPCs) throughout serial passaging, to determine whether TBX2 expression 
was specific to hemSCs.  As TBX2 is known to commonly interact with other members of the T-
box family, in particular TBX3,
122
 I also investigated whether hemSCs and bm-MPCs co-
expressed additional T-box transcription factors. My results show that TBX2 mRNA levels 
increased in bm-MPC cultures over early subculture (Figure 4.2.3).  However, at comparable 
subculture level, TBX2 mRNA were lower in normal bm-MPCs compared to hemSCs (Figure 
4.2.4).  Interestingly, TBX3 mRNA was also expressed in hemSC cultures.  When TBX2 levels 
were found to be higher in a primary cell culture, TBX3 levels were intrinsically lower, and vice-
versa (Figure 4.2.4).   
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Figure 4.2.1: TBX2 is expressed in the nucleus and the cytoplasm of primary hemSC cultures.  (A) 
Immunofluorescence staining for TBX2 (green) in hem115 primary cell culture (high TBX2 mRNA; see 
Figure 4.2.2) [DAPI nuclear stain = blue] (B) Immunofluorescence staining for TBX2 (green) in hem120 
primary cell culture (low TBX2 mRNA) [scale bare represents 100µM].  The number in the various cell 
preparations represents the de-identified patient sample number.   
 
 
            
Figure 4.2.2: TBX2 expression is variable between hemSC cultures of different patient origin. 
CD133-selected hemSC cultures from four different IH patients were assessed for TBX2 mRNA 
expression. Relative RNA normalized to β-actin; N=4; n=3.  Data expressed as mean ± SD. 
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Figure 4.2.3:  TBX2 expression increases through passage culture of bm-MPCs. 
Bone marrow mononuclear cells (bm-MNC) were cultured and assessed for TBX2 mRNA levels at 
different time points. Upon adherence and culture, bm-MNCs are referred to as bone marrow derived 
mesenchymal progenitor cells (bm-MPCs). TBX2 expression increased at early passage numbers  
(passage 3-4), and furthermore decreased throughout later passages.  Relative mRNA normalized            
to β-actin; N=1; n=3; two-tailed student’s t-tests were performed; *=p<0.05.  Data expressed as mean ± 
SD.   
 
 
 
 
Figure 4.2.4: T-box family expression profile in hemSCs and bm-MPCs 
bm-MPCs exhibit mRNA expression of TBX2 and TBX3 in early culture passages, however hemSC 
retain high levels of expression at later passage numbers.  Relative mRNA normalized to β-actin;  
bmMPC N=1; hemSC N=2; n=3.  Data expressed as mean ± SD.   
29 
 
 
 
4.3  TBX2 modulation of hemSC cell cycle regulation 
   To investigate the potentially tumourigenic role of TBX2 in hemangioma, I sought to 
determine its effect on cell cycle regulators p16 and p21, as studies have found TBX2 to repress 
p19
131
, the alternate product of the Ink4a/Arf locus transcribing p16,
137
 and p21.
135
  HemSCs 
with intrinsically higher levels of TBX2 mRNA exhibited lower levels of cell cycle regulator 
expression, while lower levels of TBX2 corresponded with increased cell cycle regulator mRNA 
levels (Figure 4.3.1; 4.2.2).  Knockdown of TBX2 via siRNA resulted in the significant 
upregulation of cell cycle regulator p16 mRNA levels (Figure 4.3.2).  Additionally, TBX2 
knockdown resulted in significantly reduced total live cell counts in hemSC cultures 24, 48, and 
72 hours after transfection (Figure 4.3.3).  At day 7, total live cell counts in hemSC cultures with 
TBX2 siRNA were comparable to those with control siRNA.   
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Figure 4.3.1:  Cell cycle regulator expression in different primary hemSC cultures. 
HemSC cultures isolated from four different IH patients were assessed for p16, p21, and cyclin              
D1 mRNA levels.  Cultures with intrinsically higher levels of TBX2 mRNA (Figure 4.2.2) have 
decreased mRNA expression of p16 and p21 compared to cultures with lower TBX2 mRNA. Relative 
mRNA normalized to β-actin; N=4; n=3.  Data expressed as mean ± SD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2:  Cell cycle regulator p16 expression is upregulated upon TBX2 knockdown                  
in hemSC.  HemSC were transfected with TBX2 siRNA and cultured in EBM2.  Expression analysis for 
cell cycle regulators p16 and p21 was performed at 48 hours post-transfection.  Only experimental 
replicates which exhibited 40% or greater TBX2 knockdown were included in analysis.  Relative mRNA 
normalized to β-actin; N=2; n=2, two-tailed student’s t-tests were performed; *=p<0.05.  Data expressed 
as mean ± SD.   
 
 
R
el
at
iv
e 
m
R
N
A
 le
ve
l 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3:  Reduced live HemSC numbers upon TBX2 knockdown.  HemSC were transfected       
with TBX2 siRNA and cultured in EBM2.  Total live cell counts were conducted at 24 hours (d1), 48 
hours (d2), 72 hours (d3) and one week (d7) post-transfection.  Only experimental replicates which 
exhibited 40% or greater TBX2 knockdown were included in analysis for d1, d2, and d3 (at d7 all 
replicates showed TBX2 mRNA levels comparable to controls).  Cells were originally transfected at a 
density of 15, 000 cells per well (96-well plate).  N=2; n=3; analysis of variance (ANOVA) followed by 
Bonferroni post-hoc analysis; *=p<0.05, **=p>0.01.  Data expressed as mean ± SEM.   
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4.4  TBX2 modulation of hemSC pluripotency 
 
   Hemangioma specimens are immunoreactive to pluripotency factors SOX2, OCT4 and 
Nanog.
31
  Furthermore, TBX2 modulation has been show to alter adipogenic differentiation of 
hemSCs.
80
  As the latter may represent a change in hemSC differentiation state, I investigated the 
effect of TBX2 on hemSC pluripotency.  HemSCs were found to express a number of 
pluripotency factors (Figure 4.4.1), and upon TBX2 knockdown pluripotency factors 
OCT4/POU5F, SOX2, and NANOG were significantly upregulated (Figure 4.4.3).  These 
findings suggest that TBX2 may regulate the stem cell phenotype of hemSCs.  In support of this 
notion, my studies also show that TBX2 co-localizes with OCT4 in the nuclei of cells lining 
vessels and interstitial cells in IH specimens (Figure 4.4.2).   
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Figure 4.4.1:  Pluripotency factor expression in different primary hemSC cultures. 
HemSC cultures isolated from four different IH patients were assessed for pluripotency factor 
mRNA expression utilizing a qBiomarker screening PCR array (IPHS-001A, Qiagen).  Relative 
mRNA normalized to GAPDH; N=4; n=3. 
 
 
     
 
Figure 4.4.2:  IH tissue sections stain positive for pluripotency marker OCT4. 
Immunofluorescence (IF) staining for Oct4 (red) and Tbx2 (green) in fixed human infantile 
hemangioma specimens [DAPI nuclear stain = bue].  TBX2 co-localized with OCT4 expression 
in the nuclei of cells lining IH vessels and interstitial cells [scale bar represents 100µM].   
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Figure 4.4.3:  Pluripotency factors are upregulated upon TBX2 knockdown in hemSCs. 
HemSCs were transfected with TBX2 siRNA and cultured in EBM2.  Gene expression analysis for 
pluripotency factors OCT4, SOX2, and NANOG was performed at 48 hours post-transfection.  Only 
experimental replicates which exhibited 40% or greater TBX2 knockdown were included in analysis.  
Relative mRNA normalized to β-actin; N=2; n=2; two-tailed student’s t-tests were performed; *=p<0.05.  
Data expressed as mean ± SD.   
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4.5  Hemangioma stem cells exhibit multi-lineage differentiation potential 
   HemSCs have previously been shown to exhibit multi-lineage differentiation potential in 
culture
16
 towards mesenchymal, neuroglial and endothelial lineages.  I confirmed the 
upregulation of lineage specific gene expression in respective induction media (Figure 4.5.1), as 
well as morphological observations during differentiation (Figure 4.5.2).  I additionally 
investigated hemSC differentiation-competence towards the hematopoietic lineage.  I compared 
CFUs in hemSCs to bm-MPCs.  bm-MNCs exhibited CFU formation in MethoCult medium at 
multiple seeding densities (Figure 4.5.3).  Intrinsically, hemSCs did not exhibit any 
hematopoietic activity in MethoCult medium (Figure 4.5.4).   
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Figure 4.5.1:  HemSC demonstrate differentiation-competence towards endothelial, neuroglial,         
and mesenchymal lineages in respective induction media.  HemSCs and bmMPCs were cultured in 
endothelial, neuroglial, osteogenic, chondrogenic, and adipogenic induction media.  Marker expression 
for each induction lineage (CD31, VE-cadherin; TUBB3, GFAP; SP7; NKX3.2, SOX9; C/EBP-α, 
PPARγ2 respectively) were assessed at d7 of  induction, comparative to control (EBM2) cultures.  
Relative mRNA normalized to β-actin; bmMPC N=1; hemSC N=2; n=3.  Data expressed as mean ± 
SD.  
 
      
 
Figure 4.5.2:  Morphological differences observed in hemSC cultures with control, neuroglial,          
and adipogenic induction media.   HemSCs cultured in control (EBM2) media exhibited spindle-shaped 
morphology, where neuronal and adipogenic cultures demonstrated ramification and lipid-droplet 
accumulation, respectively.  Bm-MPCs did not show equivalent morphological changes in neuronal 
media.  [Scale bar represents 100µM]. 
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Figure 4.5.3: Assessing plating density for optimal hematopoietic activity in MethoCult. 
bm-MNC were plated at density of 1x10e^3; 1x10e^4; 1x10e^5; 1x10e^6 cells per mL 
methylcellulose (MethoCult) media.  The maximal BFU formation observed was used to                
evaluate optimal plating density.  [Scale bar represents 100µM]. 
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Figure 4.5.4:  HemSCs do not exhibit intrinsic hematopoietic activity in MethoCult media. 
Four different hemSC primary cultures were plated in methylcellulose media for BFU colony   
observation.  Relative to bm-MPCs, no BFU formation was observed, indication the lack of 
intrinsic hematopoietic activity. [Scale bar represents 100 µM].   
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4.6  TBX2 modulation of hemSC differentiation-competence 
   To investigate the potential effect of TBX2 on differentiation competence, I performed hemSC 
differentiation following TBX2 knockdown.  My results show that TBX2 knockdown in hemSCs 
delays the upregulation of endothelial cell marker CD31 in respective induction medium, relative 
to control siRNA transfected hemSC cultures (Figure 4.6.1).  Morphologically, there were no 
obvious differences between the normal growth (control, EBM2) medium and endothelial 
differentiation medium with TBX2 knockdown at day 7 of differentiation.  Cells transfected with 
control siRNA did exhibit morphological changes in endothelial induction medium, however full 
endothelial cell differentiation was not conclusively observed. This lack of full endothelial 
differentiation in culture is consistent with our previous study. Adversely, TBX2 knockdown did 
not appear to affect neuroglial cell differentiation as assessed by GFAP and TUBB3 mRNA 
expression, as well as morphological assessment.  Interestingly, TBX2 knockdown significantly 
upregulated hematopoietic lineage specific cell surface marker CD45, as well as hematopoietic 
progenitor cell marker CD34 mRNA in control medium conditions.   
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Figure 4.6.1:  TBX2 knockdown delays CD31 expression upon culture of hemSCs in endothelial 
induction media.  HemSCs were transfected with TBX2 siRNA and cultured in endothelial induction 
media (EM = endothelial media).  Control replicates were cultured in EBM2 (CM = control media); 
transfected with control siRNA (CT).  Knockdown efficiencies were assessed at 48 hours post-
transfection; CD31 expression was assessed at day 2 (d2) and day 7 (d7) of culture with induction media.  
Only experimental replicates which exhibited 40% or greater TBX2 knockdown were included in CD31 
expression analysis at d2.  Relative mRNA normalized to β-actin; N=2; n=2; analysis of variance 
(ANOVA) followed by Bonferroni post-hoc analysis; *=p<0.05.  Data expressed as mean ± SEM.   
 
 
 
 
 
 
 
 
 
 
Figure 4.6.2:  Morphological observations of hemSC cultures after transfection with either control 
or TBX2 siRNA transfection in EBM2 and endothelial induction media. 
HemSCs cultured in endothelial induction media at day 7 after transfection with TBX2 siRNA retain 
spindle-shaped morphology.  Nuclear staining with DAPI indicates culture viability.    *Note:  percent 
TBX2 knockdown efficiency was not assessed for imaged cultures.  [Scale bar represents 100 µM].   
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Figure 4.6.3: TBX2 knockdown does not alter TUBB3 or GFAP expression upon culture of      
hemSCs in neuroglial induction media. 
HemSC were transfected with TBX2 siRNA and cultured in neuronal induction   media.  Control 
replicates were cultured in EBM2.  Knockdown efficiencies were assessed at 48 hr    post-transfection; 
TUBB3 and GFAP expression was assessed at d7 of differentiation.  Only technical replicates which 
exhibited 40% or greater TBX2 knockdown were included in marker expression   analysis.  Relative 
mRNA normalized to β-actin; N=2; n=3; analysis of variance (ANOVA) followed by Bonferroni post-hoc 
analysis; *=p<0.05.  Data expressed as mean ± SD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.4:  Morphological observations of hemSC cultures after transfection with either control 
or TBX2 siRNA transfection in EBM2 and neuroglial induction media. 
HemSCs cultured in neuronal induction media at day 7 after transfection with TBX2 siRNA demonstrate 
obvious star-shaped morphological changes.   Nuclear staining with DAPI (blue) indicates culture 
viability.  All cultures stain positive for TUBB3 (green).  *Note:  percent TBX2 knockdown efficiency 
was not assessed for imaged cultures. [Scale bar represents 100 µM]. 
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Figure 4.6.5:  HemSCs exhibit upregulated hematopoietic lineage marker expression  
upon TBX2 knockdown. 
HemSC were transfected with TBX2 siRNA and cultured in EBM2.  Knockdown efficiencies were 
assessed at 48 hours post-transfection.  Only experimental replicates which exhibited 40% or greater 
TBX2 knockdown were included in expression analysis.  Cell surface markers CD34, CD45, and ckit 
mRNA are upregulated with TBX2 knockdown at 48 hours post-transfection in control media conditions.  
Relative mRNA normalized to β-actin; N=2, n=3; two-tailed student’s t-tests were performed; *=p<0.05. 
Data expressed as mean ± SD.   
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4.7  TBX2 potentially labels hemangioma cell of origin 
 
   As TBX2 knockdown upregulated hematopoietic lineage markers in control conditions, I 
investigated potential upregulation of other associated hematopoietic genes.  I found TBX2 
knockdown to upregulate GLUT1 mRNA (Figure 4.7.1).  As previously mentioned, GLUT1 is a 
diagnostic marker of IH, however it is also used as a marker of the hematopoietic lineage-derived 
myeloid cells, monocytes.
72, 138
   Furthermore, given that hemangioma presents itself shortly after 
birth and has been diagnosed in the infant liver, I considered the possibility that hemSCs may 
arise from aberrant signaling during the transition of active hematopoiesis signaling from the 
fetal liver to the bone marrow.  Interestingly, I found both heterogenous fetal liver cells (FLC; 
unsorted) cultures and CD133-selected FLC cultures to express both TBX2 and GLUT1 (Figure 
4.7.2).  
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Figure 4.7.1: GLUT1 mRNA is upregulated in hemSC upon TBX2 knockdown. 
Known hematopoietic lineage transcription factors Runx2, Gata2/3, and SCL do not show 
significant changes in expression levels upon TBX2 knockdown, where GLUT1 is significantly 
upregulated (in hemSC cultures from Figure 4.9).  Relative mRNA normalized to β-actin; N=1, 
n=3, two-tailed student’s t-tests were performed; *=p<0.05.  Data expressed as mean ± SD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.2: Fetal liver cells express TBX2 and GLUT1 in culture. 
CD133-selected and unsorted population of FLCs express both TBX2 and GLUT1 mRNA in 
culture similar to hemSCs [FLC = unsorted fetal liver cells’ FLC133+ = sorted CD133-positive 
fetal liver cells].  Relative mRNA normalized to β-actin; N=1, n=3.  Data expressed as mean ± 
SD.   
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4.8  TGF-β modulates TBX2 expression 
 
   To investigate potential upstream modulators of TBX2, I treated hemSCs with 
agonists/antagonists of target pathways as listed in Table 2.  The Wnt pathway has been shown 
to be upstream of TBX2 in cardiac development
111
; the PI3K/Akt pathway is associated with 
upregulated VEGFR-2 signaling in tumourigenic cells 
114
; TGF-β is upstream of TBX2 in 
cardiac development
121
 and melanoma cells
122
, and is also upregulated upon involution in IH.
39
  I 
identified TGF-β treatment of hemSCs to significantly suppress TBX2 mRNA levels (Figure 
4.8.1).  I confirmed the efficacy of treatment by identifying that the addition of TGF-β pathway 
inhibitor GW788388, normalized TBX2 expression levels (Figure 4.8.2); TGF-β treatment also 
induced the significant upregulation of known downstream targets collagen I and IV mRNA 
(Figure 4.8.3).  Interestingly, the suppression of TBX2 by TGF-β treatment also induced the 
significant upregulation of pluripotency factors OCT4/POUF5, SOX2, and NANOG (Figure 
4.8.3), as seen with TBX2 knockdown (Figure 4.4.3).  Addition of PI3K pathway inhibitor PI828 
also seemed to depress TBX2 expression, however the results were not significant at p<0.05 
(Figure 4.8.1).  Additional cell preparations are needed to rule out PI3K.  Wnt agonist did not 
appear to affect TBX2 mRNA expression levels (Figure 4.8.1).   
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Figure 4.8.1: Screening for upstream modulators of TBX2 reveals TGFβ to significantly repress 
TBX2 mRNA expression.  HemSCs were cultured in EBM2 with the addition of Wnt agonist (1 μM, 
681665, EMD Millipore); TGFβ1 (10 ng/mL, 100-B, R&D Systems); and PI 3-kinase inhibitor (2 μM, PI 
828, 2814, R&D Systems).  TBX2 mRNA expression was assessed at day 3 and day 7 of culture 
(combined time point data is represented above).  Treatment with TGFβ1 ensued significant repression of 
TBX2 mRNA levels.  Relative mRNA normalized to β-actin; N=2; n=3; two-tailed student’s t-tests were 
performed; *=p<0.05.  Data expressed as mean ± SD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.2: TGFβ repression of TBX2 mRNA expression is rescued by the addition of TGFβ 
receptor inhibitor.  HemSCs were cultured in EBM2 with the addition of TGFβ1 (10 ng/mL, 100-B, 
R&D Systems); TGFβ3 (10 ng/mL, 243-B3, R&D Systems), and an inhibitor of TGF-beta type I and II 
receptor kinases (GW) (100 nM, GW788388, R&D Systems).  TBX2 mRNA expression was assessed at 
day 3 and day 7 of culture (combined time point data is represented above).   Treatment with both TGFβ1 
and TGFβ3 ensued significant repression of TBX2 mRNA expression.  The addition of TGFβ receptor 
inhibitor rescued TBX2 mRNA to control expression levels. Relative mRNA normalized to β-actin; N=2; 
n=3; two-tailed student’s t-tests were performed; *=p<0.05.  Data expressed as mean ± SD.   
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Figure 4.8.3: TGFβ repression of TBX2 mRNA expression is ensued by upregulation of 
pluripotency factor expression.  HemSCs were cultured in EBM2 with the addition of TGFβ1 (10 
ng/mL, 100-B, R&D Systems).  Pluripotency factor (OCT4/POUF5; SOX2; NANOG), collagen I (COLL 
I), and collagen IV (COL IV) mRNA expression was assessed at day 3 of culture conditions.  Treatment 
with TGFβ1 resulted in the upregulation of downstream TGFβ pathway targets COLL I and IV, as well as 
pluripotency factor mRNA expression.  Relative mRNA normalized to β-actin; N=2; n=3; two-tailed 
student’s t-tests were performed; *=p<0.05.  Data expressed as mean ± SD.   
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4.9  TGF-β modulates hemSC differentiation 
 
   To confirm whether TBX2 suppression by TGF-β may also affect hemSC differentiation-
competence, I performed cell differentiation experiments with the addition of TGF-β to induction 
media.  I focused my studies on the endothelial lineage as this lineage is the most critical during 
the proliferative phase of IH.  Furthermore, my studies with TBX2 knockdown showed delayed 
CD31 induction in cells exposed to endothelial differentiation media.  Therefore, endothelial cell 
differentiation of hemSCs provides an excellent readout of any potential effects of TGF-β.  I 
confirmed that TGF-β suppressed TBX2 expression in endothelial induction media (Figure 
4.9.1).  I also found that treatment of hemSC with TGF-β in endothelial induction media 
significantly suppresses CD31 expression at day 7 of differentiation relative to control 
endothelial media (Figure 4.9.2).  This corroborated my findings of TBX2 knockdown via 
siRNA during endothelial differentiation (Figure 4.6.1) 
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Figure 4.9.1:  Addition of TGFβ to endothelial induction media significantly represses TBX2 
expression.  HemSCs were cultured in EBM2 media (CM) and endothelial induction media (EM) with 
the addition of TGFβ1 (10 ng/mL, 100-B, R&D Systems).  TBX2 expression was assessed at day 3 and 
day 7 of culture (combined time point data is represented above).   Treatment with TGFβ1 suppressed 
TBX2 mRNA in both control and endothelial induction mediums.  Relative mRNA normalized to β-actin; 
N=2; n=3; analysis of variance (ANOVA) followed by Bonferroni post-hoc analysis; *=p<0.05.   Data 
expressed as mean ± SEM.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9.2: Addition of TGFβ to endothelial induction media significantly represses CD31 
expression of hemSC.  HemSCs were cultured in EBM2 media (CM) and endothelial induction media 
(EM) with the addition of TGFβ1 (10 ng/mL, 100-B, R&D Systems).  Endothelial lineage cell surface 
marker CD31 expression was assessed at day 3 and day 7 of culture (combined time point data is 
represented above).   Treatment with TGFβ1 significantly suppressed CD31 expression in endothelial 
induction media.  Relative mRNA normalized to β-actin; N=2; n=3; analysis of variance (ANOVA) 
followed by Bonferroni post-hoc analysis; *=p<0.05, **=p.0.01.  Data expressed as mean ± SD.   
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Chapter 5 
5  DISCUSSION 
5.1   Discussion of experimental findings 
   My findings suggest that transcription factor T-box may contribute to hemangioma 
pathogenesis by regulating both the growth and differentiation of hemSCs.   
   My studies demonstrated TBX2 to have a nuclear localization in IH specimens, displaying co-
expression with endothelial cell marker CD31 (Figure 4.1).  This indicates TBX2 is expressed in 
the endothelium of IH vessels.  Previous work in our lab has shown these CD31 positive 
endothelial cells to also co-express CD133, suggesting they are stem cells.  Isolated CD133-
expressing cells also recapitulate human hemangioma in mice.  In conjunction with the co-
expression of TBX2 and OCT4 in cells lining the lumen of IH vessels (Figure 4.4.2), I believe 
TBX2 expression to be associated with a stem-cell like phenotype in hemangioma.  The presence 
of TBX2 positivity in interstitial and perivascular cells, which appear to have the same 
localization as α-SMA positive cells (Figure 4.1), may suggest that cells other than those of the 
endothelial lineage demonstrate stem cell-like properties in hemangioma.  As the current stem 
cell of origin for hemangioma is unknown, it could be insightful to conduct a lineage analysis to 
determine whether 1) perivascular and interstitial cells in hemangioma are also derived from 
endothelial cell-forming CD133-positive cells, and 2) TBX2 expression and localization alters 
through different cell types and/or tissue layers throughout the life-cycle of the tumour.  Based 
on the work of our laboratory as well as others, I would expect that TBX2-labeled cells will give 
rise to hemangioma vessel endothelial cells as well as other cellular constituents in the tumour.  
Furthermore, based on the findings of my study, I also expect the levels of TBX2 to change upon 
cell differentiation and hemangioma involution.   
   In culture, my studies have shown TBX2 to be localized primarily in the nucleus of hemSCs, 
however one patient-derived hemSC primary cell culture also exhibited cytoplasmic as well as 
nuclear TBX2 localization (Figure 4.2.1).  Being a transcription factor, is it expected to have a 
nuclear localization when in an active state.  TBX2 has no known nuclear localization signals 
(NLS), and to date has only been found to have a cytoplasmic localization in C. elegans.
139
  This 
might suggest that TBX2 has a novel NLS sequences or that it requires binding to a NLS-
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containing protein(s) to chaperone it to the nucleus. The differences seen in TBX2 protein 
localization as well as in relative mRNA expression (Figure 4.2.2) may reflect differences from 
the patient tumour from which they were derived.  Depending on the exact stage of tumour life-
cycle upon when the hemSCs were isolated from the patient, it is possible for different primary 
cultures to retain intrinsically different TBX2 expression profiles.  If a hemSC population was 
isolated from a more proliferative tumour, this may reflect altered levels of TBX2 expression and 
localization.  Additionally, it is possible there are variable levels of TBX2 expression based on 
the clonal expansion of a particular subset of hemSCs throughout the culture expansion.  
However, it is important to note that TBX2 mRNA expression was retained at high levels 
relative to bm-MPC cultures throughout passages (Figures 4.2.3 and 4.2.4).  Additionally, prior 
studies in our lab have shown hemSCs to exhibit much higher TBX2 mRNA expression in 
culture than compared to normal endothelial cells such as cord-blood derived endothelial 
progenitors, and human microvascular endothelial cells.
80
  This suggests that TBX2 expression 
in hemSC may be associated with their pathogenicity.   
   Interestingly, TBX3 was also found to be expressed in hemSC cultures.  While TBX3 
expression in IH specimens has not been identified, it is known to be co-expressed with TBX2 in 
a number of developmental and tumourigenic processes as previously described.  It has been 
suggested that while TBX2 promotes tumour cell proliferation, TBX3 promotes endothelial-to-
mesenchymal (EMT) cell migration.
140
  Is it interesting that for my expression profile studies, 
when TBX2 mRNA was elevated in a particular hemSC culture TBX3 mRNA was decreased 
and vice-versa, levels in bm-MPCs simply dropped evenly over subculture (Figure 4.2.4).  This 
may suggest that TBX2 and TBX3 are both active in hemSC, although further analysis of TBX3 
expression in IH lesions would be necessary to confirm clinical significance of this finding.   
   What may hold potential clinical significance however, are my findings from investigating the 
effect of TBX2 expression level on cell cycle regulation.  My data suggests that TBX2 may 
repress cell cycle regulator p16, as TBX2 knockdown via siRNA significantly upregulated p16 
mRNA expression (Figure 4.3.2), while simultaneously altering the number of total live cells in 
culture.  As previously mentioned, p16 is a major target in carcinogenesis, rivaled in frequency 
only by the p53 tumour-suppressor gene. Its mechanism of action as a CDKI involves binding to 
and inactivating the cyclin D-cyclin-dependent kinase 4 (or 6) complex, rendering the 
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retinoblastoma protein inactive. This effect blocks the transcription of important cell-cycle 
regulatory proteins and results in cell-cycle arrest.
141
  As prior literature has found TBX2 to 
repress cell cycle regulators, it is a probable that the high levels of TBX2 expression in 
hemangioma may be contributing to unregulated cell growth during the proliferative phase of the 
tumour life cycle.  Supporting this, is the data by Ritter et al. which demonstrates that the 
significant decrease in TBX2 expression in IH coincides with the time of involution.
57
  However, 
direct binding of TBX2 to p16 has not been investigated in this study, and would be required to 
support p16 as a downstream target of TBX2.  Quantification of p16 protein would also be 
necessary to definitively state whether the observed changes have a significant effect on hemSC 
proliferation due to p16.  Additionally, while I observed total live cell counts to significantly 
decrease in hemSC cultures with TBX2 knockdown relative to those with control siRNA, this 
effect was lost after 7 days (Figure 4.3.3).  I believe this is likely due to the effect of the siRNA 
knockdown lasting typically 5-7 days.   
   Interestingly, as p16 mRNA was being upregulated during TBX2 knockdown, pluripotency 
factors OCT4, SOX2, and NANOG mRNA expression were upregulated in hemSC (Figure 
4.4.3).  This may suggest that TBX2 has an effect on the stem cell-like phenotype of hemSCs, 
where decreased levels of TBX2 reverts the hemSC to an undifferentiated state.  The concept of 
dedifferentiation is well known in the stem cell field, whereby cells regress from a specialized 
function to a simpler state reminiscent of stem cells.
142
  Subsequently, it may be deduced that 
elevated TBX2 promotes hemSC differentiation.  Or perhaps more correctly, their 
differentiation-competence, or potential to differentiate when supplied with the appropriate 
factors or signaling mechanisms.  Of note, the effects of TBX2 knockdown on hemSC 
pluripotency factor expression was variable depending on percent knockdown, and time in 
culture (Figure 2-App and Figure 3-App), suggesting this may be a temporary cell state, or 
even an in vitro artifact.   
   However, my studies investigating  hemSC differentiation-competence with TBX2 modulation 
cumulatively suggest the transcription factor may be involved in hemSC differentiation to some 
extent.  TBX2 knockdown resulted in the upregulation of hematopoietic lineage cell surface 
marker CD45 mRNA (Figure 4.6.5), and delayed the expression of endothelial cell surface 
marker CD31 mRNA when compared to control siRNA in respective induction media (Figure 
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4.6.1).  While this is potentially reminiscent of endothelial to hematopoietic transition (EHT), 
extensive further hemSC differentiation analysis is necessary to propose this as a plausible 
mechanism during IH involution.  Challenges encountered during these lineage analyses include 
the lack of convincing endothelial cell differentiation of hemSCs in culture with control TBX2 
levels.  Ideally, endothelial cell differentiation would be confirmed functionally by tube 
formation assay, and phenotypically by FACs sorting for endothelial cell specific lineage 
markers.  However, my assessment was restricted to the upregulation of CD31 mRNA 
expression.  Similarly, hematopoietic activity would be confirmed through function assessment 
via the formation of BFUs upon TBX2 knockdown.  While attempted, these experiments did not 
convincingly demonstrate full hematopoietic or endothelial cell differentiation.  Therefore, 
optimizing lineage induction protocols would be required for a comprehensive analysis of the 
effect of TBX2 modulation on differentiation-competence.  Nonetheless, contemplating EHT as 
a potential mechanism during upon the reduction of TBX2 during IH involution may be one 
explanation for the cell metaplasia/cell replacement observed during this transition from vascular 
to fibro-adipose tissue.  Additionally, if we consider GLUT1 a monocyte marker as suggested by 
Ritter et al.,
72
 my data suggests this is also upregulated upon TBX2 knockdown in conjunction 
with other hematopoietic lineage markers (Figure 4.7.1).  While this appears to be in 
contradiction to a study which found GLUT1-positive cells to significantly decrease upon IH 
involution,
69
 if EHT is indeed occurring during IH involution it is plausible the loss of GLUT1 
expression observed during the Bischoff study is recompensed by an increase in circulating 
GLUT1-positive hematopoietic cells.   
   To better understand the potential signaling pathway of TBX2 in IH, I tested a number of 
candidate pathway agonists/antagonists as listed in Table 2.  I identified TGF-β to significantly 
repress TBX2 expression in hemSCs (Figures 4.8.1, 4.8.2), upon which similar downstream 
effects as seen with TBX2 knockdown via siRNA were observed.  These effects included 
upregulation of pluripotency factor expression, and inhibition of CD31 mRNA expression in 
endothelial cell induction medium (Figures 4.8.3 and 4.9.2).  Interestingly, TGF-β has 
previously been shown to suppress TBX2 via TBX3 in human breast cancer cells.
122
  
Furthermore, TGF-β signaling has been associated with the suppression of endothelial cell 
differentiation.  
143, 144
  This supports our evidence that the TGF-β-TBX2 axis may be 
contributing towards hemSC lineage specification, as depicted in Figure 5.1: 
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Figure 5.1:  Schematic diagram illustrating the hypothesis and acquired findings.   
Circulating niche factor TGF-β suppresses TBX2 expression to repress hemSC proliferation       
via cell cycle regulator inhibition, as well as inhibiting endothelial lineage differentiation.        
This signaling pathway may be mediated by PI3 kinase.   
 
   While my evidence that PI3 kinase inhibition suppresses TBX2 expression in hemSCs is 
preliminary (Figure 4.8.1), it is possible there may be cross-talk between PI3 kinase and TGF-β 
pathways.  The transforming growth factor (TGF)-β and phosphoinositide 3-kinase/protein 
kinase B (PI3K/AKT) signaling pathways are used in cells to control numerous responses, 
including proliferation, apoptosis, and migration.  Previous literature has alluded to both 
modulating human embryonic stem cell differentiation, and contributing to cancer 
progression.
145, 146
  In the former studies, PI3K signaling was shown to antagonize definitive 
endoderm differentiation of human ES by attenuating the duration of Smad2/3 activation via the 
mTOR complex 2 (mTORC2).  In addition, TGF-β is known for its cytostatic effects in 
premalignant states and its pro-oncogenic activity in advanced cancers, where PI3K/AKT 
activation antagonizes the TGF-β/SMAD-induced cytostatic response.  Further studies are 
required to demonstrate direct cross-talk between the pathways in hemSCs.   
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   Identifying the molecular and biochemical mechanisms regulating hemSC differentiation 
would be a major advancement in the field, and may provide new treatment targets for IH.  In 
addition to providing insight into the etiology and pathogenesis of the tumour, this project aimed 
to characterize pathways which regulate the viability of IH stem cells.  The ability to pinpoint an 
origin of the hemSCs is ultimately restricted by the current definitions of stem cells. Based on 
current definitions for cell phenotype and respective cell lineage markers, hemSCs could be 
scientifically supported to be of mesodermal/mesenchymal stem cell origin, its pathogenesis 
originating possibly from an aberrant step in differentiation.  However, the term ‘mesenchymal’ 
seems restrictive to the mesenchymal lineage and does not truly reflect the demonstrated ability 
of hemSCs.  As the field furthers its understanding of what markers and signaling mechanisms 
are true identifiers of stem cell prospective differentiation lineages, it will advance IH research 
one step further to the origin and development of the IH pathology.  As current therapies for this 
tumour are non-specific, recognizing drugs which specifically target cells initiating the tumour 
would have far-reaching implications for clinical treatment options.   As IH affects infants at a 
critical stage during development, it is imperative to find therapies with known mechanisms of 
action, and minimal side effects.  In addition, the potential role of TBX2 as a regulator of stem 
cell differentiation-competence may have implications for research outside of IH.  If the function 
of TBX2 is conserved in normal stem cells, it may be targeted to upregulate hematopoietic 
lineage differentiation.  In summary, the potential role of TBX2 as a regulator of differentiation 
competence may have implications for the development of stem cell research, providing new 
insight into the field of regenerative medicine. 
 
5.2   Clinical implications of study 
   Identifying candidate drugs which target hemSCs may revolutionize the current treatment of 
infantile hemangioma and other stem-cell derived tumours, changing policy for the clinical 
approaches to these diseases.  As previously mentioned, the most common treatment for IH is 
currently propranolol.  I have performed pilot studies to examine the effect of propranolol 
treatment on TBX2 mRNA expression in hemSCs (Figure 5-App).  Although limited in scope, 
these studies show that propranolol upregulates TBX2 mRNA.  Therefore, it is possible that 
treatment with propranolol may in fact allow for hemSC survival in lesions.  This may be one 
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explanation for the observed recurrence of IH in certain case studies post-propranolol therapy 
cessation.  Furthermore, if TBX2 knockdown truly inhibits endothelial cell differentiation, it may 
be possible that overexpression of TBX2 promotes hemSC differentiation as well as 
proliferation.  Thus, targeting TBX2 in vivo may alter the progression of IH.  Further studies 
investigation the effects of both TBX2 knockdown and overexpression in vivo would be essential 
for identifying the true effects of modulating TBX2 on IH life-cycle.   
   Additionally, the potential role of TBX2 as a regulator of stem cell differentiation may have 
implications for many branches of stem cell research.  In particular, fields utilizing a directed 
differentiation approach to generate cells of a particular lineage, and those developing induced 
pluripotent stem cells, could benefit from targeting a transcription factor which regulates 
differentiation-competence.  Specifically, the up-regulation of hematopoietic activity observed 
with TBX2 knockdown may have implications for patients requiring HSC therapies.  Beyond the 
clinical impacts, characterizing the function of TBX2 within hemSC and normal stem cells 
would provide insight into the role of this multi-faceted transcription factor in the development 
and origin of infantile hemangioma. 
 
5.3   Future directions 
   To conclusively characterize the TBX2 signaling pathway in hemSCs, I propose utilizing 
chromatin immunoprecipitation followed by microarray hybridization (ChIP-Chip), which 
enables genome-wide analysis of transcription factor binding.
147
  This would allow for the 
identification of upstream and downstream targets of TBX2 within hemSCs, thus delineating the 
signaling mechanism by which this transcription factor influences cell fate decisions.  
Understanding the latter will allow us to target specific regulators of the proliferation and 
involution of IH.   
   I also believe it imperative to identify candidate drug therapies which target TBX2 and 
viability of hemSCs, altering the progression of IH in-vivo.  As discussed, propranolol treatment 
studies in patients have found that some IHs regrow upon cessation of propranolol treatment.
28, 29
  
This has been attributed to early treatment withdrawal and/or a long proliferating phase of IH.  
Recent work in our lab has concluded that while propranolol induces apoptosis in hemangioma 
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endothelial cells, hemSCs are resistant to caspase-3 activation by propanolol.
148
  A number of 
recent studies have also shown that propranolol treatment of normal endothelial cells as well as 
endothelial cells derived from IH specimens causes activation of caspase-3.
149, 150
  Interestingly, 
IH-derived endothelial cells are unable to recapitulate IH in vivo, as our lab has demonstrated 
with hemSCs.
16
  We have previously shown that hemSCs treated with propranolol show 
induction of anti-apoptotic pathways, including Akt (also known as protein kinase B), and 
insulin-like growth factor receptor-1 (IGFR-1).
148
  Therefore it is plausible that hemSCs may be 
responsible for the recurrence of IH upon cessation of propranolol treatment, owing to their 
ability to resist propranolol-induced apoptosis.   Interestingly, preliminary data suggests that 
hemSCs treated only with a very high dose of propranolol (100 µmol/L) show up-regulation of 
TBX2 mRNA expression (Figure 5-App).  Based on my data, I anticipate that compounds which 
induce expression of TBX2 will promote differentiation of hemSCs reflective of the involution 
process during IH.  Thus, drugs which target both the hemSC viability and the TBX2 signaling 
pathway, may prompt the most rapid regression of the tumour.     
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APPENDIX: Supplementary Data 
 
 
 
         
 
Figure 1-App: Confirmation of GLUT1-positive hemangioma specimens. 
Proliferating hemangioma and early gestation placenta (<25 weeks) specimens stain positive for the 
diagnostic marker GLUT1 (green), distinguishing the IH specimens from other types of vascular 
anomalies. Nuclear staining is seen with DAPI (blue).  [40x mag; scale bar represents 100µM; DAPI 
nuclear stain = blue]. 
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Figure 2-App:  Pluripotency factor and CD45 expression is dependent on the degree of TBX2 
knockdown.  An assessment was made for variability in induction of pluripotency factor and CD45 
mRNA expression analysis with different degrees of TBX2 knockdown and time of assessment.  Hem127 
cultures were transfected with TBX2 siRNA and cultured in EBM2.  Expression analysis was assessed at 
24 hours (d1) with 20% knockdown efficiency and 48 (d2) hours post-transfection with 43% knockdown 
efficiency.  It appears that pluripotency factors may be induced prior   to cell surface marker mRNA 
expression.  Relative mRNA normalized to β-actin; N=1; n=2.  
 
 
Figure 3-App: Pluripotency factor upregulation by TGFβ treatment. 
An assessment was made for variability in induction of pluripotency factor mRNA expression analysis 
with TGFβ time of assessment.  Hem127 were cultured in EBM2 with the addition of TGFβ1 (10 ng/mL, 
100-B, R&D Systems).  Expression analysis was assessed at day 7 of treatment with TGFβ1.  It appears 
that induction of pluripotency factors may be temporally dependent.  Relative mRNA normalized to β-
actin; N=1; n=2.   
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Figure 4-App: Hematopoietic lineage induction of hemSCs upon TGFβ treatment. 
An assessment was made for possible induction of hematopoietic lineage induction with the addition of 
TGFβ to hemSC cultures.  Hem127 were cultured in EBM2 with the addition of TGFβ1 (10 ng/mL, 100-
B, R&D Systems).  Expression analysis was assessed at day 3 of treatment with TGFβ1.  While lineage 
specific cell surface marker CD45 was not upregulated, as seen with repression of TBX2 via siRNA in 
Figure 4.9, hematopoietic transcription factor SCL is upregulated.  This may also suggest a temporally 
dependent mechanism.  Relative mRNA normalized to β-actin; N=1; n=2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-App:  Clinical perspectives – Effect of propranolol on TBX2 expression in hemSC. 
RNA isolated from hemSC cultures with the addition of current therapeutic drug compound propranolol 
(25 µM/L; 100 µM/L), kindly provided by lab member Jina Kum, was converted to cDNA and assessed 
for TBX2 mRNA expression.  High concentrations of propranolol resulted in significant upregulation of 
TBX2 expression in hemSC.  Relative mRNA normalized to β-actin; N=2; n=3; two-tailed student’s t-
tests were performed; *=p<0.05.   
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